Stockscreener 앱 받기
25.37
3.54%
-0.93
시간 외 거래:
25.37
전일 마감가:
$26.30
열려 있는:
$26.09
하루 거래량:
473.18K
Relative Volume:
1.59
시가총액:
$1.47B
수익:
-
순이익/손실:
$-118.12M
주가수익비율:
-11.13
EPS:
-2.2802
순현금흐름:
$-82.63M
1주 성능:
-6.37%
1개월 성능:
-10.89%
6개월 성능:
+52.65%
1년 성능:
+35.38%
1일 변동 폭
$24.98
$26.36
1주일 범위
$24.98
$27.17
52주 변동 폭
$14.00
$30.68
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
25.37 | 1.52B | 0 | -118.12M | -82.63M | -2.2802 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | JP Morgan | Overweight |
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Sentiment Review: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Revenue Check: Can Oculis Holding AG Equity Warrant stock double in the next year2026 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Treasury Yields: Should I invest in Oculis Holding AG before earningsMarket Trend Summary & Community Trade Idea Sharing Platform - baoquankhu1.vn
Stop Loss: Whats the MACD signal for Oculis Holding AG2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Oculis Holding AG Presents Promising Phase 2 ACUITY Trial Results for Privosegtor at NANOS 2026 Meeting - Quiver Quantitative
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting - The Manila Times
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting - GlobeNewswire Inc.
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Oculis board member buys company stock on March 12 and 13 - Stock Titan
Oculis Holding AG (OCS) reports Q4 loss, tops revenue estimates - MSN
Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 63.9% - MarketBeat
Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates - MSN
Risk Off: Can Oculis Holding AG beat the S P 500Portfolio Risk Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (OCS) Movement - Stock Traders Daily
Aug Opening: What is the implied volatility of Oculis Holding AG Equity WarrantWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com Nigeria
Biopharma companies hire new legal executives - BioXconomy
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
OCS: Late-stage pipeline targets DME, dry eye, and neuroprotection, with major data readouts in 2024 - TradingView
[144] Oculis Holding AG SEC Filing - Stock Titan
A Look At Oculis Holding (OCS) Valuation After Breakthrough Therapy Status And Q4 2025 Update - Sahm
Oculis (OCS) – Research Analysts’ Recent Ratings Updates - Defense World
Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price Pullback - Yahoo Finance
Oculis (NASDAQ:OCS) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Lifesci Capital Has Negative Estimate for Oculis Q1 Earnings - Defense World
Lifesci Capital Estimates Oculis' Q1 Earnings (NASDAQ:OCS) - MarketBeat
HC Wainwright Weighs in on Oculis' Q1 Earnings (NASDAQ:OCS) - MarketBeat
Why Oculis (OCS) Is Down 6.2% After New Equity Programs To Fund Late-Stage Trials - Sahm
Oculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
H.C. Wainwright raises Oculis stock price target to $44 on trial progress By Investing.com - Investing.com South Africa
Oculis Holding AG Announces Participation in Upcoming Investor Conferences and Highlights Late-Stage Pipeline Developments - Quiver Quantitative
Oculis to Participate in Upcoming Investor Conferences - Yahoo Finance
Oculis Holding AG renews $100 million at-the-market offering program - Investing.com Australia
Stifel raises Oculis stock price target to $50 on pipeline progress - Investing.com Nigeria
Oculis Holding AG renews $100 million at-the-market offering program By Investing.com - Investing.com South Africa
Oculis Files 2025 Financials and Renews $100 Million ATM Program - TipRanks
Oculis Holding (NASDAQ: OCS) widens loss but ends 2025 with strong cash and $100m ATM capacity - Stock Titan
Oculis price target raised to $44 from $42 at H.C. Wainwright - TipRanks
RSU awards vest for Oculis board director Arshad Khanani - Stock Titan
Oculis (NASDAQ: OCS) 2025 20-F details losses, cash and trials - Stock Titan
HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price - MarketBeat
Oculis (NASDAQ:OCS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Chardan Raises Price Target on Oculis Holding to $53 From $51, Keeps Buy Rating - marketscreener.com
Oculis Holding's Q4 Net Loss Narrows; Plans Phase 3 Trial Readouts For OCS-01 In Q2,2026 - Nasdaq
Oculis Reports Q4 and Full-Year 2025 Results, Shares Update - InvisionMag.com
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline - TipRanks
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year - TipRanks
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update - The Manila Times
[6-K] Oculis Holding AG Current Report (Foreign Issuer) | OCS SEC FilingForm 6-K - Stock Titan
Eye drug firm Oculis eyes 3 major 2026 vision milestones after $119M loss - Stock Titan
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):